Aché keen on acquisitions in pharmaceutical sector
A Aché poderia fazer aquisições no setor farmacêutico
Intel ID : 237454
| Synopsis |
|
Aché, a pharmaceutical laboratory based in Guarulhos, São Paulo state, could carry out acquisitions in the sector, as published by newspaper Valor Econômico on 7 June 2016, citing its director, Mônica Branco. According to the news, the company has plans to expand in the dermatology segment, and will begin innovation and expansion of its partnership with the medical community and its product distribution. Also if there is the opportunity, the company will acquire products or companies. As far as companies, the process is still in an embryonic stage, but Aché is beginning to look at alternatives. According to Mônica Branco, "We are mapping out areas where we may evolve through acquisitions".
(content in portuguese)
A Aché, laboratório farmacêutico com sede em Guarulhos no estado de São Paulo, poderia fazer aquisições no setor, segundo publicou o Valor Econômico no dia 07 de junho de 2016, citando a Diretora da Aché Derma, Mônica Branco. De acordo com a notícia, a empresa, que pretende crescer no mercado de dermatologia, vai lançar mão de inovação, ampliação da parceria com a classe médica e da distribuição de seus produtos. Também se houver oportunidade, a empresa poderá fazer aquisição de produtos ou companhias. Nessa última frente, o processo ainda está em estágio embrionário, mas a Aché já começa a olhar alternativas. Segundo Mônica Branco, "Estamos mapeando como podemos evoluir em aquisições". |
| Intel ID | 237454 | |
| Value | ND | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - Aché
(31 Dec 2020) |
Net Debt: EUR 96,17m Exchange Rate:
|
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
10.01.13 Testing, Inspection and Certification (TIC) Services 10 Business Services / 10.01 Business & Professional Support Services 15.04.01 Cosmetics & Perfumes 15 Consumer Products & Services / 15.04 Consumer Nondurables 15.04.03 Personal Care Products 15 Consumer Products & Services / 15.04 Consumer Nondurables 15.06.01 Colleges & Universities 15 Consumer Products & Services / 15.06 Education & Training Services 30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.99 Other Biotechnology & Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.02.02 Eyewear 30 Healthcare / 30.02 Healthcare Equipment & Supplies 30.02.03 Healthcare Product Distributors 30 Healthcare / 30.02 Healthcare Equipment & Supplies 30.02.04 Medical Diagnostic Equipment 30 Healthcare / 30.02 Healthcare Equipment & Supplies 30.02.05 Medical Monitoring Equipment 30 Healthcare / 30.02 Healthcare Equipment & Supplies 30.02.06 Non-Durable Medical Supplies 30 Healthcare / 30.02 Healthcare Equipment & Supplies 30.02.07 Surgical Equipment 30 Healthcare / 30.02 Healthcare Equipment & Supplies 30.02.08 Orthopedic & Therapeutical Equipment 30 Healthcare / 30.02 Healthcare Equipment & Supplies 30.02.99 Other Healthcare Equipment & Supplies 30 Healthcare / 30.02 Healthcare Equipment & Supplies 40.03.07 IT Consulting, Development & Outsourcing 40 Information Technology / 40.03 Internet, Software & IT Services |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.